Last reviewed · How we verify
cadonilimab combined TPC chemotherapy
cadonilimab combined TPC chemotherapy is a PD-1 inhibitor Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic triple-negative breast cancer. Also known as: cadonilimab combined NAB-paclitaxel, cisplatin, and capecitabine.
Cadonilimab is a monoclonal antibody that targets the PD-1 receptor, thereby inhibiting the PD-1/PD-L1 pathway and enhancing anti-tumor immune response.
Cadonilimab is a monoclonal antibody that targets the PD-1 receptor, thereby inhibiting the PD-1/PD-L1 pathway and enhancing anti-tumor immune response. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic triple-negative breast cancer.
At a glance
| Generic name | cadonilimab combined TPC chemotherapy |
|---|---|
| Also known as | cadonilimab combined NAB-paclitaxel, cisplatin, and capecitabine |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, cadonilimab prevents its interaction with PD-L1, allowing T cells to recognize and attack cancer cells. This mechanism is thought to be responsible for the therapeutic effects of cadonilimab in combination with TPC chemotherapy.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic triple-negative breast cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Vomiting
- Rash
- Pyrexia
- Cough
- Dyspnea
- Headache
- Muscle pain
Key clinical trials
- A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. (PHASE2)
- TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cadonilimab combined TPC chemotherapy CI brief — competitive landscape report
- cadonilimab combined TPC chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about cadonilimab combined TPC chemotherapy
What is cadonilimab combined TPC chemotherapy?
How does cadonilimab combined TPC chemotherapy work?
What is cadonilimab combined TPC chemotherapy used for?
Who makes cadonilimab combined TPC chemotherapy?
Is cadonilimab combined TPC chemotherapy also known as anything else?
What drug class is cadonilimab combined TPC chemotherapy in?
What development phase is cadonilimab combined TPC chemotherapy in?
What are the side effects of cadonilimab combined TPC chemotherapy?
What does cadonilimab combined TPC chemotherapy target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer, PD-L1 positive
- Indication: Drugs for Metastatic triple-negative breast cancer
- Also known as: cadonilimab combined NAB-paclitaxel, cisplatin, and capecitabine
- Compare: cadonilimab combined TPC chemotherapy vs similar drugs
- Pricing: cadonilimab combined TPC chemotherapy cost, discount & access